It is intended to examine the safety and efficacy of desensitization therapy by GB-0998 (intravenous immunoglobulin) for the anti-donor antibody positive recipient in need of pre-transplant desensitization. Patients with positive FCXM-T after performing twice double filtration plasmapheresis (DFPP) therapy will receive GB-0998 1g/kg/day for four days.

Inclusion Criteria:

• Patients with stage 4 or 5 on the CKD classification.
• Of the patients that wants a living-donor kidney transplant of ABO blood type compatible, patients with positive FCXM-T and negative CDC-T to the donor.
• Patients with positive FCXM-T after performing twice DFPP therapy

Exclusion Criteria:

• Patients who had taking to continue immunosuppressive drugs or steroids within 4 weeks before obtaining informed consent.
• Patients who had IVIG therapy, or plasmapheresis therapy within 12 weeks before to informed consent.
• Patients who had Rituximab within 6 month before to informed consent.
• Patients who have undergone splenectomy.
• Patients with severe hepatic disorder or severe heart disorder.
• Patients with receiving treatment of malignancy.
• Patients with high risk of thromboembolism.
• Patients with history of shock or hypersensitivity to GB-0998.
• Patients with hereditary fructose intolerance or IgA deficiency.
• Patients with pregnant or probably pregnant.